HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.
Print Friendly, PDF & Email

NCT/Study#

NCT04002401 /

KT-US-471-0114

A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Axicabtagene Ciloleucel In Combination With Either Rituximab Or Lenalidomide In Subjects With Refractory Large B-Cell Lymphoma (ZUMA-14)

DISEASE GROUP:
Lymphoma
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: